Mounjaro ® and its delivery device base are registered trademarks owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates. Mounjaro is available by prescription only. Zepbound ® and its delivery device base are registered trademarks owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates. Zepbound is ...

1 day ago · Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker came out with a mostly better-than-expected 2025 forecast.. Sales of Lilly’s top-selling product, the diabetes treatment Mounjaro, jumped 60% to $3.53 billion in the final quarter of 2024 while its obesity treatment counterpart Zepbound brought in …

1 day ago · Eli Lilly Q4 Earnings: Strong Demand For Mounjaro But Prices Dip, Forecasts Over 30% Jump In 2025 Sales On Newer Medicines. On Thursday, Eli Lilly and Co (NYSE:LLY) stock is trading higher after ...

1 day ago · Eli Lilly Mounjaro Zepbound GLP-1 Lilly on Thursday reported fourth-quarter revenue of $13.53 billion, a steep 45% increase over the sum the Indianapolis-based drugmaker generated during the same ...

1 day ago · Eli Lilly's Q4 revenue rose 45% YoY to $13.53B, driven by Mounjaro and Zepbound. Adjusted EPS hit $5.32, beating the $4.94 consensus. 2025 guidance projects $58B-$61B in sales, with a 32% growth ...

1 day ago · Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss and diabetes drug Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion.

LillyDirect ® is a registered trademark owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates. ... You Are Now Leaving Mounjaro.lilly.com. You've clicked on a link for a third-party site, which Lilly USA, LLC does not control, influence, or endorse. Lilly is not responsible for any content on this third-party site ...

Jan 25, 2025 · While Novo Nordisk's Ozempic is the most mainstream GLP-1 medication, Eli Lilly (LLY-1.48%) has two blockbuster weight loss drugs of its own: Mounjaro and Zepbound.

Mounjaro is a once-weekly injectable prescription medicine to improve blood sugar (glucose) in adults with type 2 diabetes mellitus. It should be used along with diet and exercise. Mounjaro (tirzepatide) injection - Lilly Medical

Mounjaro (tirzepatide) 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg per 0.5 mL injection, is a prescription medicine for adults with type 2 diabetes used along with diet and exercise to improve blood sugar (glucose).